Clinical Evidence: Insights From Early Trials of CDH6-Targeted Therapies
Joyce F. Liu, MD, MPH
CDH6 in Focus: Advancing Biomarker-Driven Strategies for Platinum-Resistant Ovarian Cancer
Kathleen Moore, MD, MS
Transformative Insights: Latest Evidence for B7-H3 ADCs From WCLC and ESMO 2025
Luis Paz-Ares, MD, PhD
Lauren A. Byers, MD
Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From WCLC 2025
Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From ESMO 2025
Clinical Implications of Emerging Data on B7-H3–directed ADCs in the Future of ES-SCLC
Global Perspectives on Perioperative Immunotherapy in LA HNSCC
Kevin J Harrington, PhD, FRCP, FRCR, FRSB
Christophe Le Tourneau, MD, PhD
Advanced Therapeutic Strategies and Resistance Mechanisms in CLL
Shankara Paneesha, MD FRCP FRCPath
Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma
John M. Kirkwood, MD
Sapna Patel, MD
Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma
Novel Therapies in Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Stephen Liu, MD
Joshua K. Sabari, MD
Susan Scott, MD
Clinical Data Prompting Guideline Updates for Subcutaneous ICIs in Melanoma
Hussein Tawbi, MD, PhD
Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management
Paolo A. Ascierto, MD
Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma
Emerging Therapeutic Developments in Non-Targetable Metastatic NSCLC
MET and Other Emerging Targets in Metastatic NSCLC
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We're glad to see you're enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.